Previous close | 5.40 |
Open | 5.40 |
Bid | 10.00 |
Ask | 0.00 |
Strike | 27.00 |
Expiry date | 2024-08-16 |
Day's range | 5.40 - 5.40 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Key Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to their...